Company Achieves Milestones in Both Clinical ProgramsInitiates Mipletamig Phase 1b/2 Clinical Trial, "RAINIER," in Frontline Acute Myeloid Leukemia, Informed by…
Secured multi-regional patent assets, strengthening Ainos' AI Nose technology.Expanded VELDONA® patent portfolio with a new invention patent for treatments and…
FORT LAUDERDALE, FL / ACCESSWIRE / November 6, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering…
Business Activity Index at 57.2%; New Orders Index at 57.4%; Employment Index at 53%; Supplier Deliveries Index at 56.4% TEMPE,…
SHELTON, CT / ACCESSWIRE / November 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader…
SEATTLE WA AND LUND, SWEDEN / ACCESSWIRE / October 29, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) and Alligator Bioscience AB…
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it will present…
SHELTON, CT / ACCESSWIRE / October 22, 2024 / NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), a clinical stage…
Company to conduct a Phase 1 Drug-Drug Interaction StudyPhase 2 filing on track for Q1 2025 SOUTH SAN FRANCISCO, Calif.,…
CALGARY, Alberta, Oct. 17, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX…